Correction to: Cardiovasc Diabetol (2017) 16:128 https://doi.org/10.1186/s12933-017-0610-y
Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below), as the original version contained a mistake.
The original article has been corrected.
References
-
1.
Leiter LA, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(6):1145–53.
-
2.
Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
-
3.
White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.
-
4.
Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.
-
5.
Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373(3):232–42.
-
6.
Pfeffer MA, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.
-
7.
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
-
8.
Marso SP, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375(4):311–22
-
9.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
-
10.
Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
-
11.
Marso SP, et al. Efficacy and safety of degludec versus glargine in Type 2 diabetes. N Engl J Med. 2017;377(8):723–32.
-
12.
Neal B, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644-57.
-
13.
Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;S2213-8587(17):30309–1.
Reference
Schnell O, Rydén L, Standl E, Ceriello A, on behalf of the D&CVD EASD Study Group. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2017;16:128. https://doi.org/10.1186/s12933-017-0610-y.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1186/s12933-017-0610-y.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Schnell, O., Rydén, L., Standl, E. et al. Correction to: Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 16, 150 (2017). https://doi.org/10.1186/s12933-017-0633-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12933-017-0633-4